{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:54:23Z","timestamp":1784159663296,"version":"3.55.0"},"reference-count":22,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIHR BRC"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,9,12]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the distribution of the EULAR SSc Impact of Disease (ScleroID) and its domain questions in very early (Ve), limited (lc) and diffuse cutaneous (dc) subsets, its value in reflecting clinical severity, and to assess its sensitivity to change and minimal clinically important difference (MCID) in a 12-month interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with ScleroID questionnaires from the observational cohort STRIKE were included in the study. Changes (\u0394) were calculated as the difference between 12-month follow-up and compared MCIDs of the other measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data were available for 271 patients, 69 with Ve, 139 lc and 63 dc systemic sclerosis (SSc). Median (IQR) ScleroID scores were progressively higher in the 3 subsets with 2.1 (3.6) for VeSSc, 3.4 (4.4) for lcSSc and 4.7 (4) for dcSSc (p&lt;0.001). ScleroID showed strong content validity against clinical measures. Patients with high disease activity had significantly higher ScleroID scores than low ones (p=0.003). Presence of digital ulcers, pulmonary disease or small intestinal bacterial overgrowth was all reflected in higher scores in their relative domains (p&lt;0.005 for all). Accordingly, ScleroID scores and its relative domains showed high correlations with all other patient-reported outcomes (PROs) (p&lt;0.05). Changes in ScleroID strongly correlated with changes in clinical measures and other PROs with specific thresholds identified for MCID changes in Health Assessment Questionnaire Disability Index, the University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0 and Cochin Hand Function Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ScleroID demonstrates strong correlation with validated clinical measures and responsiveness to changes in standard of care, supporting its use in both clinical practice and trials. ScleroID captures the multidimensional burden of SSc regardless of disease subsets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-005999","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:50:16Z","timestamp":1760093416000},"page":"e005999","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Cross-validation and sensitivity to change of EULAR ScleroID as a measure of function and impact of disease in patients with systemic sclerosis"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5703-6739","authenticated-orcid":false,"given":"Seda Yurumez","family":"Colak","sequence":"first","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds Faculty of Medicine and Health, Leeds, UK"},{"name":"Gulhane Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Di Donato","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds Faculty of Medicine and Health, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bixio","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds Faculty of Medicine and Health, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley-Anne","family":"Bissell","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds Faculty of Medicine and Health, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Barnes","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Countess of Chester Hospital NHS Foundation Trust, Chester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Nisar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Luton and Dunstable University Hospital NHS Foundation Trust, Luton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds Faculty of Medicine and Health, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Denton","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal Free London NHS Foundation Trust, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-2283","authenticated-orcid":false,"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds Faculty of Medicine and Health, Leeds, UK"},{"name":"NIHR Biomedical Research Centre, LTHT, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2026010700550862000_11.4.e005999.1","first-page":"156","article-title":"Current management strategies for systemic sclerosis","volume":"32","author":"Nihtyanova","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2026010700550862000_11.4.e005999.2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/BOR.0000000000000971","article-title":"Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials","volume":"35","author":"Ross","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"2026010700550862000_11.4.e005999.3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/2397198320904178","article-title":"Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials","volume":"5","author":"Saketkoo","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"2026010700550862000_11.4.e005999.4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003216","article-title":"Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets","volume":"10","author":"De Lorenzis","year":"2024","journal-title":"RMD Open"},{"key":"2026010700550862000_11.4.e005999.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.24730"},{"key":"2026010700550862000_11.4.e005999.6","first-page":"S98","article-title":"Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler\u2019s Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud\u2019s Condition Score (RCS)","volume":"63 Suppl 11","author":"Pope","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026010700550862000_11.4.e005999.7","doi-asserted-by":"crossref","unstructured":"Del Galdo F , Lescoat A , Conaghan PG , et al . EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 2024. doi:10.1136\/ard-2024-226430","DOI":"10.1136\/ard-2024-226430"},{"key":"2026010700550862000_11.4.e005999.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220702"},{"key":"2026010700550862000_11.4.e005999.9","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-023-03063-1","article-title":"Characteristics of ScleroID highlighting musculoskeletal and internal organ implications in patients afflicted with systemic sclerosis","volume":"25","author":"Nagy","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2026010700550862000_11.4.e005999.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep202"},{"key":"2026010700550862000_11.4.e005999.11","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-025-03524-9","article-title":"Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease","volume":"27","author":"Distler","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"2026010700550862000_11.4.e005999.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev016"},{"key":"2026010700550862000_11.4.e005999.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh070"},{"key":"2026010700550862000_11.4.e005999.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219100"},{"key":"2026010700550862000_11.4.e005999.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424"},{"key":"2026010700550862000_11.4.e005999.16","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00244-7"},{"key":"2026010700550862000_11.4.e005999.17","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"2026010700550862000_11.4.e005999.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054866"},{"key":"2026010700550862000_11.4.e005999.19","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/annrheumdis-2023-eular.2262","article-title":"POS1246\u2005EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN SUBGROUPS BY DISEASE ACTIVITY INDEX","volume":"82","author":"Herrick","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026010700550862000_11.4.e005999.20","first-page":"501","article-title":"Outcome measurements in scleroderma: results from a delphi exercise","volume":"34","author":"Gazi","year":"2007","journal-title":"J Rheumatol"},{"key":"2026010700550862000_11.4.e005999.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110225"},{"key":"2026010700550862000_11.4.e005999.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01692-0"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:55:18Z","timestamp":1767776118000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-005999"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005999","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}